In fact, a meta-analysis noted that anti-inflammatory therapies, inhibiting the NLRP3/IL-1β/IL-6/CRP pathway, were able to prevent MI and coronary re-vascularization in CHD (Pan et al., 2025). This evidence concerns the gene CRP and coronary artery disorder.